Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Clarient extends pending offer, files amendment to Solicitation/Recommendation Statement

Clarient, Inc. announced today the extension of the current pending offer by Crane Merger Sub, Inc., an indirect wholly-owned subsidiary of General Electric Company to acquire all of the outstanding shares of capital stock of the Company.

4 Dec 2010

New standard treatment for early stage breast cancer

Spanish Oncology has established a new standard treatment for Breast Cancer at early stages thanks to the results of the study 9805/Target 0 funded by Spanish Breast Cancer Research Group and sponsored by Sanofi Aventis.

4 Dec 2010

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

A newly published study in the Lancet suggested that a first-line treatment regimen including Zometa (zoledronic acid) significantly improved overall survival and progression-free survival in newly diagnosed multiple myeloma patients compared with a regimen that included oral clodronate. The impact on survival was independent of the effect of Zometa on bone complications (also known as skeletal-related events or SREs).

4 Dec 2010

New clues into mechanisms underlying antiphospholipid syndrome

Thanks to findings by UT Southwestern Medical Center researchers, individuals with a potentially life-threatening condition predisposing them to blood clots, or thrombosis, might someday receive therapy to prevent the condition.

4 Dec 2010

Key findings on plasma cell disorders to be presented at American Society of Hematology Annual Meeting

Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic services, announced that Dr. Raul Braylan, Hematopathologist and Clinical Medical Director of Hematopathology Services, will present key findings related to plasma cell disorders at the upcoming 52nd Annual Meeting and Exposition of the American Society of Hematology.

4 Dec 2010

Loyola nurses honored

Loyola University Health System revenue specialist Judy Williams, RN, CEN, TNS, recently took on a nontraditional nursing role, which resulted in a significant cost savings for the organization. Williams oversees fiscal responsibility for the Emergency Department. In this position, she has identified opportunities to overcome billing obstacles through intradepartmental collaboration and nurse education on proper documentation for reimbursement.

3 Dec 2010

Experts reach consensus on beneficial effects of Soy

According to the December 2010 Journal of Nutrition Supplement titled, "Soy Summit: Exploration of the Nutrition and Health Effects of Whole Soy," consensus has been reached among leading soy science experts surrounding three main areas of debate: soy and women's health, soy and heart health, and soy and overall nutrient adequacy. Leading soy experts agree that including soyfoods in a balanced diet will have beneficial effects and improve nutrient intake among the U.S. population.

3 Dec 2010

Cell Therapeutics submits pixantrone NDA application to treat non-Hodgkin's lymphoma

Cell Therapeutics, Inc. today announced that it has submitted a formal appeal to the Office of New Drugs in the U.S. Food and Drug Administration's Center for Drug Evaluation and Research regarding the agency's decision from earlier this year on the pixantrone New Drug Application to treat relapsed/refractory aggressive non-Hodgkin's lymphoma.

3 Dec 2010

Sagent launches chemotherapy agent topotecan hydrochloride for injection

Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced U.S. FDA approval and launch of its topotecan hydrochloride for injection, a chemotherapy agent, in conjunction with the innovator's patent expiry. Sagent's topotecan is available in 4 mg single-dose latex-free vials.

3 Dec 2010

Alcohol drinking pattern impacts coronary heart disease

A fascinating study published in the BMJ shows that although the French drink more than the Northern Irish each week, as they drink daily, rather than more on less occasions, the French suffered from considerably less coronary heart disease than the Northern Irish.

3 Dec 2010

Sirnaomics cemented partnership with Chinese pharmaceutical to develop siRNA therapeutics

Sirnaomics, Inc. announced today that the company has cemented a partnership with a Chinese pharmaceutical company for development of its small interfering RNA (siRNA) therapeutic (STP705) for scarless wound healing.

3 Dec 2010

TUM physicist's new approach expected to improve image contrast with low radiation

The DFG cited Pfeiffer's research in biomedical imaging, and in particular his pioneering work in X-ray phase-contrast imaging. His systematic approach has laid the foundation for applications of this technique in medicine and industry, where it is expected to deliver improved image contrast with lower doses of radiation.

3 Dec 2010

Geron commences enrollment in imetelstat Phase 2 clinical trial for metastatic breast cancer

Geron Corporation today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), in combination with paclitaxel (with or without bevacizumab) in patients with locally recurrent or metastatic breast cancer.

3 Dec 2010

Amgen to present data on Nplate studies for chronic ITP at ASH Annual Meeting

Amgen today announced that it will present data from several key Nplate (romiplostim) studies at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 4-7, 2010, in Orlando, Fla.

2 Dec 2010

AstraZeneca announces FDA Advisory Committee meeting outcome for vandetanib NDA

AstraZeneca today announced the outcome of the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee meeting to discuss the New Drug Application (NDA) for AstraZeneca's investigational drug, vandetanib, for the treatment of patients with unresectable (non-operable) locally advanced or metastatic medullary thyroid cancer (MTC).

2 Dec 2010

ROCHE, Baylor Research Institute partner in human immunology research

Baylor Research Institute (BRI), the research arm of Baylor Health Care System, announced today that it has formed a three-year partnership with Roche (SIX: RO, ROG; OTCQX: RHHBY) to jointly develop programs emerging from the human immunology platforms developed at the Baylor Institute for Immunology Research (BIIR), a component of BRI.

2 Dec 2010

New clue in leukemia mystery

There is new hope for people with acute myelogenous leukemia (AML), a fast-growing cancer of the blood and bone marrow. Research led by Weill Cornell Medical College and published today in the online edition of the journal Cancer Cell reveals a surprising and unexpected cancer-causing mechanism. The investigators discovered that newly identified mutant enzymes in AML create a chemical poison to cause leukemia. Their findings should prove useful in treating patients by providing a molecular target against which to develop new drugs against one subset of AML as well as other cancers.

2 Dec 2010

News segment highlights value of hyperthermia for treatment of breast cancer

BSD Medical Corp. today reported that hyperthermia treatment delivered at Texas Oncology-Baylor Charles A. Sammons Cancer Center in Dallas was highlighted in a television segment titled, "Turning up the heat on breast cancer," which aired on WFAA-TV, a Dallas/Fort Worth ABC affiliated television station.

2 Dec 2010

European Commission approves Pfizer's SUTENT for pancreatic neuroendocrine tumors

Pfizer Inc. announced today that the European Commission has approved SUTENT (sunitinib malate) for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors (NET) with disease progression in adults.

2 Dec 2010

AVEO to present data on tivozanib Phase 1b trial for breast cancer at SABCS Symposium

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with paclitaxel (Taxol), a standard chemotherapy regimen, will be presented during the 33rd Annual San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2010 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

2 Dec 2010

Oncology News and Research

Further Reading

Clarient extends pending offer, files amendment to Solicitation/Recommendation Statement

New standard treatment for early stage breast cancer

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

New clues into mechanisms underlying antiphospholipid syndrome

Key findings on plasma cell disorders to be presented at American Society of Hematology Annual Meeting

Loyola nurses honored

Experts reach consensus on beneficial effects of Soy

Cell Therapeutics submits pixantrone NDA application to treat non-Hodgkin's lymphoma

Sagent launches chemotherapy agent topotecan hydrochloride for injection

Alcohol drinking pattern impacts coronary heart disease

Sirnaomics cemented partnership with Chinese pharmaceutical to develop siRNA therapeutics

TUM physicist's new approach expected to improve image contrast with low radiation

Geron commences enrollment in imetelstat Phase 2 clinical trial for metastatic breast cancer

Amgen to present data on Nplate studies for chronic ITP at ASH Annual Meeting

AstraZeneca announces FDA Advisory Committee meeting outcome for vandetanib NDA

ROCHE, Baylor Research Institute partner in human immunology research

New clue in leukemia mystery

News segment highlights value of hyperthermia for treatment of breast cancer

European Commission approves Pfizer's SUTENT for pancreatic neuroendocrine tumors

AVEO to present data on tivozanib Phase 1b trial for breast cancer at SABCS Symposium

Cancer Research - Second Edition eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News